Decrease in von Willebrand factor levels after a high-monounsaturated-fat diet in non-insulin-dependent diabetic subjects.
High levels of von Willebrand factor (vWF) have been reported in diabetics with vascular complications, suggesting a role for this protein in the development of cardiovascular complications in non-insulin-dependent diabetes mellitus (NIDDM). Recently, a diet rich in monounsaturated fatty acids (MUFA) has been found to improve glycemic control and decrease diurnal blood pressure as compared with a high-carbohydrate (H-CHO) diet in NIDDM subjects. To study the impact of MUFA on the hemostatic system, we compared the levels of vWF, fibrinogen, fibronectin, and alpha 2-macroglobulin before and after 3 weeks on a high-MUFA (H-MUFA) diet and on an isocaloric H-CHO diet in 15 NIDDM subjects. In a crossover study, the patients were randomly assigned to a H-CHO diet (50% carbohydrate, 30% fat [10% MUFA]) or a H-MUFA diet (30% carbohydrate, 50% fat [30% MUFA]). Before and on the last day of the two diets, vWF, fibrinogen, fibronectin, and alpha 2-macroglobulin levels were measured. The H-MUFA diet caused a decrease in vWF from 1.31 +/- 0.08 to 1.13 +/- 0.08 U/mL (P < .004), whereas an unchanged level was observed after a H-CHO diet (1.19 +/- 0.11 v 1.25 +/- 0.11 U/mL, NS). The relative changes in vWF during 3 weeks on a H-MUFA and on a H-CHO diet attained -12.5% +/- 3.2% versus 5.7% +/- 3.5%, respectively (P < .0001). Furthermore, unchanged levels of fibrinogen, fibronectin, and alpha 2-macroglobulin were seen after usage of the two diets.(ABSTRACT TRUNCATED AT 250 WORDS)
Rasmussen
O
O
Medical Department of M (Diabetes & Endocrinology), Aarhus Kommunehospital, Denmark.
Thomsen
C
C
Ingerslev
J
J
Hermansen
K
K
D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000178:diet therapy*; D003925:Diabetic Angiopathies / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D004730:Endothelium, Vascular / Q000187:drug effects*; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D000511:alpha-Macroglobulins / Q000032:analysis; D014841:von Willebrand Factor / Q000032:analysis*
D004040:Dietary Carbohydrates; D004042:Dietary Fats, Unsaturated; D005229:Fatty Acids, Monounsaturated; D005353:Fibronectins; D000511:alpha-Macroglobulins; D014841:von Willebrand Factor; D005340:Fibrinogen